106  (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts' reporting. Issue 6 (27th May 2022)

• Record Type: Journal Article
• Authors: Rog, David; Hobart, Jeremy; Clements, Jake; McGregor, Jamie; Mazibrada, Gordon; Rajkumar, Arthi; Mathews, Joela
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
• Page Start: A134
• Page End: A134
• Publication Date: 2022-05-27
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-ABN.431
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Introduction: GIRFT utilises comparator data to assess variation in practice, including HES data. Context and accuracy underpin meaningful data analysis. Dashboards enable similar components of service delivery to be compared and benchmarked. Methods: DR, JH and JM, worked with JC, to develop a bespoke MS HES dashboard, utilising IQVIA's HES dataset (from 2014), in Tableau, for people with MS accessing hospital care in England. Multiple filters relevant to clinical practice were created. Results: Consistent MS-related activities were very inconsistently reported across Trusts. Some Trusts report infusion-related activities as elective day cases, others as elective inpatients, some report as both. For the 2019/2020 financial year, the MS variances listed below were compared for 4 Trusts (Barts Health, Univer- sity Hospitals Birmingham, University Hospital Plymouth, Salford Royal). Elective waiting list: 42%, 57%, 9%, 8%; Elective planned admissions: 38%, 3%, 5%, 74%; Elective Booked admissions: 0%, 6%, 52%, 3%. These probably represent systematic differences in reporting admission methods, rather than significant differ- ences in types of admissions, but clarification is required. Conclusion: Trusts report the same activity differently in HES. We recommend enabling MS services to examine, critique and benchmark their clinical practice routinely. Cautious interpretation of MS outcome comparisons is required until data are consistently reported. Acknowledgement Roche Products Ltd provided funding but had no control over dashboard content, maintenance or distribution. david: [e-mail] 78